In Chicago, a groundbreaking study offers new potential for individuals suffering from spinal cord injuries. Investigators at the Shirley Ryan Ability Lab are pioneering research on a novel substance called NVG291, which may change the landscape for patients struggling with these debilitating conditions.
Scientific Chair Dr. Monica Perez, an expert in the recovery of arm and hand functions, highlights the significance of the trial. The focus is to enhance patients’ practical abilities, such as the basic power to grasp objects or regain the autonomy of walking, which are often impaired by spinal cord injuries.
Dr. Perez’s team utilizes electrophysiological measurements to track the progress of participants, examining the amplitude of neural signals before and after the treatment to gauge its efficacy. Unlike other treatments, NVG291 does not aim to mend damaged nerves directly. Instead, it interferes with growth inhibitors that prevent the body’s natural repair mechanisms from functioning post-injury. Administered subcutaneously, NVG291 intends to clear these blockers and catalyze the
Source: WGN TV Chicago